UNSPSC 51332848: Fluphenazine decanoate

This classification denotes an antipsychotic agent with the molecular formula C32H44F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FMU62K1L3C, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but more generally known as fluphenazine decanoate, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Fluphenazine decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02230MIG.

UNSPSC 51332848 Fluphenazine decanoate is a Commodity code. State and local governments do not use this code to procure the antipsychotic medication itself; instead, recent opportunities tagged with this code reveal a mismatch between the code's nominal pharmaceutical scope and actual procurement activity. The most recent opportunity (Seminole County, Florida, IFB60459723LAS) solicits Naloxone and drug deactivation systems—emergency medications and harm-reduction equipment unrelated to fluphenazine. A second-recent opportunity (Texas HHS Commission, RFI HHS0017013) seeks information on direct-to-manufacturer pharmacy benefit program models, and a third (Minnesota MMCAP, RFP S1070000015802) targets generic multi-source pharmaceuticals and OTC products through cooperative purchasing. None of these solicitations directly specify fluphenazine decanoate procurement. Issuing bodies in the recent record include state health agencies, county health departments, and multistate cooperative purchasing alliances serving state and local facilities, but fluphenazine does not emerge as a defined procurement line item.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County's Naloxone procurement (due July 26, 2023) represents a county-level public health buy through competitive IFB; the Texas HHS Commission's RFI (due April 3, 2026) signals early-stage state-level interest in restructuring pharmacy benefit programs; and Minnesota's MMCAP RFP (due March 26, 2026) establishes multi-state contracts for generic pharmaceuticals through authorized wholesalers effective July 1, 2026. The code shows little relevant recent activity for fluphenazine decanoate specifically, suggesting either inactive demand, misclassification in state procurement systems, or procurement through broader generic pharmaceutical frameworks rather than individual drug codes.